151,700 Shares in Lifecore Biomedical, Inc. $LFCR Purchased by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. acquired a new position in Lifecore Biomedical, Inc. (NASDAQ:LFCR) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 151,700 shares of the company’s stock, valued at approximately $796,000. Tocqueville Asset Management L.P. owned about 0.40% of Lifecore Biomedical at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Legion Partners Asset Management LLC boosted its stake in Lifecore Biomedical by 0.7% during the 3rd quarter. Legion Partners Asset Management LLC now owns 4,461,823 shares of the company’s stock worth $32,839,000 after purchasing an additional 30,000 shares during the last quarter. BlackRock Inc. acquired a new stake in Lifecore Biomedical in the second quarter valued at approximately $10,569,000. Vanguard Group Inc. raised its stake in Lifecore Biomedical by 0.8% in the third quarter. Vanguard Group Inc. now owns 1,622,769 shares of the company’s stock valued at $11,944,000 after buying an additional 12,851 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Lifecore Biomedical by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 779,642 shares of the company’s stock worth $6,379,000 after purchasing an additional 6,013 shares during the last quarter. Finally, State Street Corp increased its position in Lifecore Biomedical by 8.5% during the fourth quarter. State Street Corp now owns 585,386 shares of the company’s stock worth $4,788,000 after buying an additional 46,102 shares during the period. Institutional investors and hedge funds own 83.36% of the company’s stock.

Lifecore Biomedical Stock Performance

LFCR stock opened at $4.52 on Friday. The stock has a market capitalization of $171.08 million, a P/E ratio of -4.22 and a beta of 1.08. The company has a 50 day moving average price of $4.86 and a two-hundred day moving average price of $5.31. Lifecore Biomedical, Inc. has a one year low of $3.63 and a one year high of $8.98.

Lifecore Biomedical (NASDAQ:LFCR) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.19) EPS for the quarter, meeting the consensus estimate of ($0.19). The business had revenue of $34.17 million during the quarter, compared to analysts’ expectations of $34.18 million. Research analysts forecast that Lifecore Biomedical, Inc. will post -1.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on LFCR shares. Weiss Ratings restated a “sell (d-)” rating on shares of Lifecore Biomedical in a research report on Tuesday, August 4th. Wall Street Zen upgraded shares of Lifecore Biomedical from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Zacks Research raised shares of Lifecore Biomedical from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Finally, Barrington Research raised their price target on Lifecore Biomedical from $6.00 to $6.50 and gave the stock an “outperform” rating in a report on Tuesday, June 16th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $6.50.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.